
Liraglutide
Liraglutide is a licensed medicine with substantial randomized evidence: dedicated obesity trials at the higher dose, and pooled analyses showing...
About:
A GLP-1 receptor agonist approved for type 2 diabetes and, at higher dose, for weight management.
What does this peptide do?
Supported by randomised human trials. Research focuses on type 2 diabetes and weight management.

Type 2 diabetes
Approved for type 2 diabetes.

Weight management
Approved at higher dose for weight management.
Evidence grade
AHighest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Liraglutide is a licensed medicine with substantial randomized evidence: dedicated obesity trials at the higher dose, and pooled analyses showing reduced cardiovascular events across the GLP-1 class.
- This is what a well-evidenced compound looks like, and the contrast with most of this library is the point.
Who should avoid it
- People who are pregnant or breastfeeding
- Children outside licensed indications
- People with a history of pancreatitis, pending clinician advice
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.

How to store this peptide
Supplied as a prefilled pen or vial in the licensed product. Store refrigerated before first use and follow the product leaflet.
Lyophilized storage
Refrigerate at 2–8 °C in the original carton. Do not freeze.
Reconstituted storage
Once in use, may be kept below 30 °C for the period stated on the product label.
Storage Handling
Protect from light. Do not use if it has been frozen.
Related research
Related research is coming soon for this peptide.


